NCT05727839View on ClinicalTrials.gov

Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors

PHASE1UnknownINTERVENTIONAL
Enrollment

156

Participants

Timeline

Start Date

February 24, 2023

Primary Completion Date

July 24, 2025

Study Completion Date

August 24, 2025

Conditions
Cutaneous TumorMalignant Solid Tumor
Interventions
DRUG

JCXH-211 Injection

JCXH-211 administered once every 28 days

Trial Locations (1)

510060

RECRUITING

Sun Yat-sen University Cancer Center, Guangdong

Sponsors
All Listed Sponsors
lead

Immorna Biotherapeutics, Inc.

INDUSTRY

NCT05727839 - Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors | Biotech Hunter | Biotech Hunter